Bulk Inquiry
GSK 1838705A
- GSK 1838705- Soluble in DMSO
- MF: C27H29FN8O3
- MW: 532.57
Description
More Information
| Parent CAS No. | 1116235-97-2 |
|---|---|
| Chemical Name | 2-(2-(1-(2-(dimethylamino)acetyl)-5-methoxyindolin-6-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-6-fluoro-N-methylbenzamide |
| SMILES | C1(OC)C(NC2N=C(NC3C(C(=O)NC)=C(F)C=CC=3)C3C=CNC=3N=2)=CC2N(C(=O)CN(C)C)CCC=2C=1 |
| MFCD | MFCD19443644 |
| InChi | InChI=1S/C27H29FN8O3/c1-29-26(38)23-17(28)6-5-7-18(23)31-25-16-8-10-30-24(16)33-27(34-25)32-19-13-20-15(12-21(19)39-4)9-11-36(20)22(37)14-35(2)3/h5-8,10,12-13H,9,11,14H2,1-4H3,(H,29,38)(H3,30,31,32,33,34) |
| InChiKey | HZTYDQRUAWIZRE-UHFFFAOYSA-N |
| CID | 25182616 |
| Short Description | IGF1R/IR inhibitor |
References
- S.D. Chamberlain et al. Optimization of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidine IGF-1R tyrosine kinase inhibitors towards JNK selectivity. Bioorg. Med. Chem. Lett. 2009, 19, 360-364.
- P. Sabbatini et al. GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers. Mol. Cancer Ther. 2009, 8, 2811-20.
Related Products
| AXON ID | NAME | FROM PRICE |
|---|---|---|
| 1416 | NVP-TAE684 |
From $55.00 |
| 1660 | Crizotinib |
From $88.00 |
| 1702 | OSI 906 |
From $66.00 |
| 1884 | Alectinib |
From $77.00 |
| 2005 | ASP 3026 |
From $88.00 |
| 2153 | AZD3463 |
From $115.50 |
| 2224 | LDK 378 |
From $104.50 |
| 2238 | NT 157 |
From $104.50 |
| 2294 | KRCA 0008 |
From $104.50 |
| 2600 | PF 06463922 |
From $115.50 |
| 2978 | Brigatinib |
From $88.00 |
| 3341 | PQ401 |
From $110.00 |
| 3830 | GSK1904529A |
From Inquiry |
| 3931 | CEP-28122 |
From Inquiry |
| 3973 | XL-228 |
From Inquiry |
| 4146 | LGX818 |
From Inquiry |
Other Categories
Are you sure you would like to remove this item from the shopping cart?
This item is a part of the approved quote. Removing it will remove all quote items from the cart.


